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Multiple sclerosis (MS) is an inflammatory chronic disorder. It manifests itself by 
an inflammation of the central nervous system and by a deregulation of the immune 
system, leading to lesions in axons. The diagnosis of MS is clinical, however, paraclinical 
tests are fundamental. In the laboratory study of cerebrospinal fluid and serum, the 
oligoclonal IgG bands (OCB IgG) analysis can evaluate intrathecal synthesis. We 
analyzed the prevalence of OCB IgG in MS and clinically isolated syndrome (CIS), the 
role of OCB IgG in the MS prognosis and CIS conversion, as well as its correlation with 
latitude effect. From 93 articles, 32 were used according to the inclusion criteria. The 
statistical analysis was made in the IBM SPSS version 23 software. The prevalence of 
OCB IgG in MS was 82,6% and in CIS 66,8%. A non-linear correlation was observed 
between the prevalence of OCB IgG and the conversion from CIS to MS. No correlation 
was found between the presence of OCB IgG and MS prognosis. The main prevalence of 
OCB IgG was observed in the northern hemisphere, and at a latitude of 40° or higher. 
The presence of OCB IgG in cerebrospinal fluid is connected to MS. OCB IgG positivity 
is linked to conversion from CIS to MS. This study was limited due to the small quantity 
of articles used in the prognosis analysis. There was not enough data to confirm the 
latitude effect.
Keywords: Multiple Sclerosis; Clinically Isolated Syndrome; OCB IgG; Prevalence; 
Prognosis
Introduction
The Multiple Sclerosis (MS) is an autoimmune and 
demyelinating inflammatory chronic disorder that, as it develops, 
gains a neurodegenerative capability. MS affects the central nervous 
system, being potentially the most common cause of neurologic 
deficiency in young adults [1]. It manifests itself by an inflammation 
of the CNS and by a deregulation of the immune system, leading to 
lesions in axons and therefore, damage of myelin along with axonal 
loss. The healing process of the inflamed axons forms multifocal 
sclerotic plaques that characterize the disease [1]. Different forms 
of presentation for MS have been identified. Relapsing remitting 
MS (RRMS) it’s the most usual appearing in 85% of patients [2]. It 
consists in the occurrence of relapses, followed by total or partial 
recovery, the remission period. At this stage it’s possible to provide 
the patient with complementary medication, reducing the severity 
of the relapse, regardless of the disease modifying therapy, aimed 
 
at the prevention of new relapses. MS affects twice as many women 
than men [1,2]. In about 65% [1] of patients with RRMS the disease 
develops into secondary progressive MS (SPMS), in which the clinical 
episodes become more frequent, leading to axonal degeneration and 
the possible presentation of signs of gliosis [2]. Primary progressive 
MS (PPMS) appears in 15% [2] of the patients, consisting of the 
constant progression of the disease, without remission or relapses, 
resulting in increased disability faster than RRMS. Clinically isolated 
syndrome (CIS) is defined as the first clinical episode that presents 
characteristics that suggest a MS diagnosis. In these episodes the 
optical nerve, the brainstem and the spinal cord can be affected [3]. 
Approximately 85% of patients develop MS from a CIS episode [4]. 
MS diagnosis is clinical, however, it is fundamental to use certain 
paraclinical tests [5,6]. The magnetic resonance imaging (MRI) 
allows the detection of lesions in the CNS, whereas the analysis 
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of biological fluids, cerebrospinal fluid (CSF) and serum evaluates 
the presence or absence of oligoclonal IgG bands (OCB IgG). The 
search for oligoclonal IgG bands (OCB IgG), made in CSF and serum, 
allows the examination of existence of intrathecal inflammation. 
The intrathecal generation of immunoglobulins type IgG is done 
by clones of B lymphocytes, after exposure to unidentified antigens 
present in the CNS, this secretion generally remains throughout 
MS progression [2]. According with Thompson et al. [5], and after 
the 2017’s McDonald criteria revision, these paraclinical tests are 
essential not only for a more immediate diagnosis but also for a 
differential diagnosis. Apart from the OCB IgG search, in the CSF 
analysis the absence of findings such as neutrophils, atypical cells 
or elevated protein concentration, allows to discard the presence of 
other diseases. In addition to the laboratorial tests, a simple brain 
MRI or in association with spinal cord MRI are recommended, 
once they can locate lesions and detect its dissemination in time, 
indicating if the lesions are active [5]. Once MS is diagnosed, an 
evaluation of the clinical state of the patient is made based on the 
Expanded Disability Status Scale (EDSS) [7]. EDSS was developed 
by Kurtzke, allowing the quantification of the disability based on 
clinical findings [8]. Through CSF and serum analysis, it is possible 
to assess the intrathecal presence of OCB IgG. Its importance 
comes from the 90% of MS cases that have presence of OCB IgG, 
even though this percentage can vary according to the geographic 
location of the patients [1,9]. 
The standard technique for this detection is isoelectric focusing 
(IEF) on agarose gel followed by immunoblotting [10,11] or 
immunofixation [12,13], allowing the immunoglobulin separation 
through the isoelectric point. IEF followed by immunoblotting has 
various advantages when compared with other electrophoresis 
variations, such as higher sensitivity, detection of a larger number 
of OCB IgG as well as an easier distinction and a more accurate 
interpretation [9]. According to Schwenkenbecher et al. [14]. 
OCB IgG sensitivity in MS patients is 98,5%. This search is always 
done in CSF and serum simultaneously, since a positive result in 
both biologic fluids may exclude the possibility of a MS diagnosis 
[15]. The interpretation of the results is made though 5 different 
patterns of OCB IgG. Thus, the absence of OCB in CSF and serum 
indicates a negative pattern, type 1. In type 2 the presence of two 
or more BOC restricted to CSF suggests CNS inflammation, due to 
intrathecal synthesis of IgG. This “positive” type 2 is the classical 
pattern observed in MS and CIS patients. The presence of OCB in 
both biologic fluids, but with a higher number in the CSF than in 
the serum, is classified as type 3 “higher than” and it indicates 
intrathecal IgG synthesis as well. In the “mirror” pattern, the 
presence of identical OCB is detected both in CSF and serum, it is 
labelled as type 4 and points to the presence of a systemic reaction. 
At last, type 5 shows the presence of monoclonal bands both in 
CSF and serum, and it can be related to monoclonal gammopathy 
[9,10,12,16,17]. It is important to have in mind that the OCB IgG 
presence is not specific to MS once OCB IgG can be detected in other 
inflammatory diseases, such as systemic lupus erythematosus or 
neurosarcoidosis [9]. Studies show that MS prevalence is higher in 
individuals originated from northern countries (Scandinavia and 
United Kingdom) and less common in tropical areas (Brazil, India 
and Saudi Arabia [18-20]. Genetic susceptibility and the surrounding 
environment are factors that can cause such prevalence [2,18,20]. 
The HLA-DRB1 gene was associated with a higher susceptibility 
to the disease while the Epstein-Barr virus has been shown to be 
involved in some cases of MS [2]. The prevalence of MS is higher 
in northern Europe and northern America countries (>30 cases in 
100000), average in south Europe, Australia and New Zealand (5 to 
30 cases in 100000) and lower in Asia, South America and Africa 
(<5 cases in 100000) [21,22]. There is also the record of differences 
of OCB IgG detection in MS patients that can be related to latitude. 
There is a lower prevalence of OCB IgG in Asian countries, about 
35% to 46%, when compared to western countries, close to 90% 
[9,23]. Thus, in Scandinavia, United Kingdom and Canada more 
than 90% of patients have OCB IgG positivity and in south Europe 
(such as Portugal, Spain and Turkey) only between 81% to 87% are 
OCB IgG positive [24,25]. However, there are exceptions detected 
in Sardinia, for example, where there is a high prevalence of MS 
(151,9 cases in 100000) [26,27]. There are also some studies 
defending that the presence of OCB IgG in CIS patients is connected 
to a development into a MS diagnosis [22,28]. Regarding the MS 
prognosis, it is expected that patients with negative OCB IgG have 
a slower progression compared with positive OCB IgG patients 
[9,29]. This prognosis can be evaluated by measuring EDSS 
progression for a determined follow-up period. Although OCB IgG 
presence alone can’t make a MS diagnosis, this analysis is important 
as a support to clinical diagnosis due to its common appearance 
in an initial stage of the disease. The present study aims for the 
clarification of positive OCB IgG prevalence in MS and CIS patients 
and their association with the disease prognosis and conversion to 
CIS, it is also intended to study the relation between latitude and 
MS and CIS patients.
Material and Methods
Data Search
EndNote software was used to search online articles through 
PubMed. For the search terms like “multiple sclerosis”, “oligoclonal 
bands”, “cerebrospinal fluid” and “clinically isolated syndrome” 
were used. After this initial research, the abstracts were analyzed to 
select the articles that were in accordance to the inclusion criteria.
Inclusion Criteria
The search was conditioned by pre-defined inclusion criteria 
in order to obtain a solid sample. These inclusion criteria include 
articles with a minimum sample of 10 patients. In cases that the 
same articles include MS and CIS patient groups, these groups must 
be defined, and the results must be presented separately. The same 
procedure applies to articles that study the prognosis, thus the 
patients with progressive forms of MS had to be divided (PPMS and 
SPMS). In order for the results to be consistent, only the articles 
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in which the technique used was IEF followed by immunoblotting 
were selected. Most of the included articles were published after 
2000, however, the articles related to the understanding of the 
disease and technique are prior to 2000.
Article Selection
Of the 93 articles initially selected, 67 were entirely analyzed. 
This exclusion of articles was made based on information from the 
abstracts, permitting the discard of articles that did not contain 
relevant information for this analysis. From these 67 articles, 32 
were selected to include in this study. Therefore, articles that used 
IEF followed by immunofixation (n=12), that used electrophoresis 
with silver stain (n=7), articles which did not specify the technique 
used or that used different techniques in its patient population 
(n=14) and articles that only selected patients with positive or 
negative OCB IgG (n=2), were rejected (Figure 1). For the OCB 
IgG prevalence in MS examination 22 articles were used, as well 
as 13 others for the OCB IgG prevalence in CIS. Regarding the 
MS prognosis, 4 articles were analyzed, and for the evaluation of 
CIS to MS conversion 10 articles were used. For the analysis of 
the relationship between latitude and OCB IgG, 20 articles were 
resorted to for MS and 11 for CIS (Table 1). For the analysis of the 
latitude effect, the location of each study was found, and the latitude 
was then determined through Google Maps, which provided a value 
that was rounded up to the unit. Articles that had samples from 
more than one country were excluded, since it was not possible to 
clarify the location of each population.
Figure 1: Article selection.
Table 1: Association of the 67 articles according to the inclusion criteria.
Articles
OCB IgG prevalence in MS
Frau J, et al. [30]; Becker M, et al. [31]; Lourenco P, et al. [32]; Rojas JI, et al. [33]; Caudie C, et al. [35]; Bourahouri A, et 
al. [36]; Andlovic A, et al. [37]; Sa MJ, et al. [38]; Franciotta D, et al. [56]; Dujmovic I, et al. [57]; Sellebjerg F, et al. [58]; 
Chang KH, et al. [59]; Gama PD, et al. [60]; Villar LM, et al. [61]; Caudie C, et al. [62]; Villar LM, et al. [63]; Presslauer S, 
et al. [64]; Brandao CO, et al. [65]; Krakauer M, et al. [66]; da Gama PD, et al. [67].
OCB IgG prevalence in CIS Kuhle J, et al. [4]; Kinoshita M, et al. [22]; Tintore M, et al. [34]; Andlovic A, et al. [37]; Schwenkenbecher P, et al. [46]; Masjuan J, et al. [47]; Gama PD, et al. [60].
MS prognosis Frau J, et al. [30]; Becker M, et al. [31]; Lourenco P, et al. [32]; Rojas JI, et al. [33].
Conversion from CIS to EM Kuhle J, et al. [4]; Kinoshita M, et al. [22]; Tintore M, et al. [34]; Schwenkenbecher P, et al. [46]; Masjuan J, et al. [47].
Effect of latitude in MS
Frau J, et al. [30]; Becker M, et al. [31]; Lourenco P, et al. [32]; Rojas JI, et al. [33]; Caudie C, et al. [35]; Bourahouri A, et 
al. [36]; Andlovic A, et al. [37]; Sa MJ, et al. [38]; Franciotta D, et al. [56]; Dujmovic I, et al. [57]; Sellebjerg F, et al. [58]; 
Chang KH, et al. [59]; Gama PD, et al. [60]; Caudie C, et al. [62]; Villar LM, et al. [63]; Presslauer S, et al. [64]; Brandao 
CO, et al. [65]; Krakauer M, et al. [66]; da Gama PD, et al. [67].
Effect of latitude in CIS Kinoshita M, et al. [22]; Tintore M, et al. [34]; Andlovic A, et al. [37]; Schwenkenbecher P, et al. [46]; Masjuan J, et al. [47]; Gama PD, et al. [60].
Statistical Analysis
The IBM SPSS version 23 software was used for statistical 
analysis. To evaluate the difference between OCB IgG prevalence 
in MS and CIS, t-Student for 2 independent samples test was 
used. Graphics were built to understand the relation between the 
variables. The results were presented as: mean ± standard deviation 
and values of p<0.05 were considered significant.
Results
Based on the analysis of the 32 articles, 8179 MS patients and 
2460 CIS patients were studied. The ratio between the number of 
women and men is 2.28±0.36, being that, in every article studied, 
the number of women is higher than men. The global mean age of 
the patients is 33±2.97 years.
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Prevalence of OCB IgG in MS and CIS
OCB IgG prevalence in MS was 82.6% and in CIS was 66.8%. 
Thus, the presence of OCB IgG in patients diagnosed with MS was 
shown to be superior when compared to patients with CIS (p=0,000; 
φ=10635; t=73.015), with a mean difference of 15.8%.
Conversion from CIS to MS
The articles studied take the clinical diagnosis of MS as 
conversion, which can be supported by MRI and laboratorial tests. A 
non-linear correlation between OCB IgG prevalence and conversion 
from CIS to MS was checked. From positive OCB IgG patients, 73.2% 
were converted to MS as compared to 25.1% with negative OCB IgG 
patients, during a follow-up of 50.4±8.7 months. The conversion 
of CIS to clinically defined MS was related to the global mean 
age of each study. In positive OCB IgG, patients a conversion rate 
higher between 31 and 34 years old was observed, being that the 
study with a lower conversion rate was also the one that presents 
a lower mean age of 30 years old. In negative OCB IgG patients, 
the conversion rate is only higher than 40% in one of the studies 
with a mean age of 34 years old, no relation was verified between 
conversion and age of the patients.
MS Prognosis
One paper [30] from Sardinia analyzed the time the study 
group took to reach EDSS 3 and 6 during a mean follow-up time of 
6 years. The prevalence of OCB IgG was 83.8%. In this particular 
study, 95% of patients had RRMS and the remaining had PPMS, 
being that 82.7% take DMT. After the follow-up, 24.85% reached 
EDSS 3 and 9.15% reached EDSS 6. Although no relation with 
statistical significance was found between these results and the 
presence or absence of OCB IgG, it was found between patients 
with a higher age onset and the presence of PPMS. Becker et al. [31] 
had as a purpose to observe the relation between the presence of 
OCB IgG and time to reach EDSS 4. 87% of patients had positive 
OCB IgG and 85.7% had RRMS and the remaining had PPMS. 34.9 
% of patients reached EDSS 4 after follow-up. It wasn’t found any 
relation between time to reach EDSS 4 and presence or absence of 
OCB IgG. Another investigation [32] analyzed disease progression 
through EDSS and disease ratio, as well as through the proportion 
of patients that reached EDSS 6 in 10 years into the disease. OCB 
IgG prevalence in this study was 72.5% and a higher presence of 
oligoclonal bands in patients with PPMS, when compared to RRMS 
and SPMS patients was observed. No association between presence 
or absence of OCB IgG and disease progression was confirmed. 
Lastly, a study by Rojas et al. [33] related OCB IgG presence with 
PPMS conversion to SPMS and with progression to an EDSS 6. The 
prevalence of oligoclonal bands was 90%, and it was observed that 
there was a higher percentage of patients with positive OCB IgG 
(31%) that reached EDSS 6 during follow-up, when compared to 
negative OCB IgG (10%). Although with no statistical significance, 
it was also observed that more patients with positive OCB IgG 
converted to SPMS (33.5%) compared to 15% of negative OCB IgG. 
This study concluded that OCB IgG presence is related with a worse 
prognosis.
Effect of Latitude
The articles included in this study were based on populations 
from diverse countries. Brazil and Argentina represent the 
southern hemisphere, and of the northern hemisphere, articles 
from Europe, Asia and north America were present, including the 
following countries: England, Germany, Denmark, Austria, Slovenia, 
Serbia, Czech Republic, France, Spain, Italy, Portugal, Japan, Taiwan 
and Canada. The higher prevalence of OCB IgG was found mostly in 
the northern hemisphere at a latitude higher than 40° (Figure 2).
Figure 2: Effect of latitude and OCB IgG prevalence.
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Discussion
Although the presence of OCB IgG isn’t by itself responsible 
for MS diagnosis, this analysis is important as a support to clinical 
diagnosis due to its common appearance in the initial stage of 
the disease. For this reason, studying the presence of OCB IgG 
is relevant in order to clarify its role and its clinical meaning for 
this disease. The articles used in this study present a population 
distribution with a higher number of women than men affected 
by MS and CIS [34,35], which meets previous investigations [1,2]. 
The global mean age was 33 years old, representing the majority 
of people that present signs of MS, which is within the range of 
20 to 40 years old [1]. The global result of prevalence of OCB IgG 
in MS patients, in every study included, is of 82,6% [9,12,36,37]. 
According to Sa et al. [38] this prevalence is similar to the results 
obtained by IEF followed by immunoblotting. However, in this study 
there are results from articles based on Asian populations, in which 
was found a smaller OCB IgG prevalence. Studies from Kikuchi 
et al. [39] and Siritho et al. [40] indicate that these populations 
commonly have a lower percentage of positive OBC IgG in MS 
patients. On the other side, Link et al. [9] indicates that the method 
used for OCB IgG search has an important role in prevalence, since 
the use of different techniques will have a lower sensitivity, thus 
making the result comparison unreliable. Regarding the negative 
OCB IgG patients, it is also possible for some to not have a correct 
MS diagnosis, since there is the hypothesis that other diseases, 
with similar MRI findings to MS, may be present [41]. Positive OCB 
IgG in CIS were associated to a higher risk of conversion to MS, 
since a larger risk related to band absence was shown. According 
to Tintoré et al. [34] OCB IgG presence is related to MS evolution, 
possibly being more relevant than visible MRI lesions since patients 
with a normal MRI and positive OCB IgG manifest higher risk of a 
second clinical episode, relatively to patients with a normal MRI 
but with negative OCB IgG. These signs can be important because, 
through OCB IgG search, the possibility of clinical MS diagnosis 
can be admitted while in the absence of OCB IgG, suggesting the 
presence of other diseases. 
The percentage of conversion from CIS to MS can vary 
according to different studies, due to the follow-up period and to 
the use of different criteria for MS diagnosis [22]. Besides the OCB 
IgG presence, there are other variables studied while associating 
the conversion to MS in CIS patients, such as the number and 
type of lesions identified by MRI [42] and environmental factors, 
including elevated values of antibodies anti-virus Epstein-Barr and 
lower values of vitamin D [43,44]. Kuhle et al. [4] concludes that 
individuals with CIS with a higher conversion to MS risk present 
positive OCB IgG and an elevated lesion number in MRI. The same 
study also indicates that the patient age at disease onset is related 
with risk of conversion, having higher ages a lower probability 
of conversion [45]. Thus, mean age of patients with conversion 
to MS was 31 years old compared with the 33 years old of the 
patients that did not converted during follow-up. In this study it 
wasn’t possible to present strong results regarding age and risk 
of conversion association, however the articles that report higher 
conversion percentage have a global mean age between 31 and 
34 years old [46,47]. The meaning of OCB IgG presence regarding 
disease progression isn’t unequivocal, since the studies carried in 
this field don’t always have identical results. The literature studied 
uses different parameters, hindering result comparison, thus 
making a statistical analysis not possible. EDSS is used to verify the 
time that patients take, since disease onset, to reach a certain value 
in this scale. This allows the evaluation of the possible association 
between oligoclonal bands and a faster disease evolution. Besides 
EDSS, it is also possible to verify if patients initially diagnosed with 
RRMS progress to SPMS, a more aggressive form of the disease. 
Regarding PPMS the disease development is faster, since there isn’t 
a remission period in this form of MS, so the presence of OCB IgG 
that, according to Lourenço et al. [32] is more elevated than in other 
MS types, may not be associated with disease progression. PPMS is 
generally acknowledged in patients with older ages when compared 
with RRMS [48]. Two of the articles studied, Frau et al. [30] and 
Becker et al. [31], conclude that patients with higher ages in disease 
onset are associated with a worse prognosis, since these individuals 
reached a higher EDSS value (3 and 4, respectively) in less time. 
Other studies [49,50] support this conjecture, while admitting 
that RRMS patients and older ages in disease onset manifest more 
susceptibility to a faster progression. Although women are more 
affected by the disease than men, according to Frau et al. [30] they 
have a less aggressive disease course, but bibliography that could 
support this conclusion was not found. On the contrary, Debouverie 
and collaborators [50] indicates that differences between women 
and men concerning disease progression were not found. Regarding 
OCB IgG Zeman et al. [29] and Stendahl Brodin et al. [51] defend 
that the absence of OCB IgG is related with a better MS prognosis. 
According to Lourenço et al. [32] OCB IgG positivity isn’t associated 
with disease progression, however Joseph et al. [52] demonstrated 
that negative OCB IgG patients had a better prognosis by studying 
the time that took to reach EDSS levels 4 and 6. Rojas et al. [33] 
even concludes that OCB IgG presence is related to disease 
aggressiveness by considering conversion from RRMS to SPMS 
and progression to EDSS 6. It must be taken into consideration 
that some of these studies did not analyze every factor that can 
interfere in disease prognosis, such as the use of DMT that, by 
preventing new relapses, can delay disease progression. MS has 
its highest prevalence in the northern hemisphere, for that reason 
the included studies are mostly from that area. The reason for this 
phenomenon is unknown, however it’s observed that according to 
an individual’s location the disease manifestation can vary. Certain 
genetic and environmental factors are responsible for triggering 
MS onset. Compston et al. [18] admitted the existence of a relation 
between MS and alleles from major histocompatibility complex 
(MHC), being that this association is stronger in northern European 
populations. Therefore, the study of certain genetic characteristics 
becomes more relevant, such as the presence of HLA DRB1 complex 
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alleles, that are proved to be related to disease development [53]. 
Regarding environmental factors, Marrie et al. [20] reflected over 
some studies that concluded that lower levels of ultraviolet radiation 
are associated with MS presence, which can explain the lower MS 
prevalence in tropical areas. There’s also evidence of the regulatory 
effects that vitamin D has in the cells of the immune system, which 
may justify why individuals with lower levels of vitamin D are more 
associated to MS [54,55]. Besides these factors, one MS type was 
identified as more common in Asian countries, named optic-spinal 
[9], which may explain why OCB IgG prevalence in these regions is 
lower, since this type of the disease rarely presents positive OCB IgG 
[23]. In this study it wasn’t possible to observe if the effect between 
latitude and OCB IgG prevalence is significative. Nevertheless, it 
was verified that the regions where OCB IgG prevalence was more 
elevated were Italy [56], Serbia [57] and Denmark [58], and the 
lower prevalence in Taiwan [59] and Brazil [60-74].
Conclusion
The presence of OCB IgG in CSF is associated with MS, being 
also an important support for the diagnosis of MS while in presence 
of CIS. Regarding association of OCB IgG with disease prognosis, it 
is considered that the present study was limited due to the reduced 
number of included articles. The papers used in evaluation of 
prognosis are more recent publications, which can show a growing 
realization of the importance of these essays. This suggests that 
OCB IgG search will be increasingly supportive to clinical practice 
and leading to a more directed therapeutic. It is considered that 
there is a need for more extensive investigations in time as well 
as more complete ones in the MS prognosis field. Regarding the 
effect of latitude, it was noted that there’s some variation in OCB 
IgG prevalence according to geographic location, however it can be 
stated that, based on the articles analyzed, not enough information 
has been obtained to prove so.
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